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Although immunoglobulin measurements are a surrogate
marker of immunity, there is no reliable predictor of
whether a HIV-positive patient will mount adequate sero-14th International Congress on Infectious Diseases (ICID) Abs
lower thoracic spinal cord with hyperintense signal in T2
left hemicord. The major capsid protein (VP1) of the Sabin
virus T1 isolated in feces showed a 96.5% genetic similarity
to Sabin 1 vaccine strain (a 3.5% genetic divergence in this
region).
Conclusion: The occurrence of iVDPVs appears to be very
rare; the majority of patients stopped excretion of the virus
after a certain period or have died. The overriding factor for
the emergence of all VDPVs is the same as for WPV circula-
tion, i.e., low routine OPV coverage rates in children. Thus,
a community can become susceptible to the emergence of
all types of VDPV producing an impact in the public health
of the population. New polio vaccination strategies should
be considered to avoid future VDPV cases and to be aligned
WHO endgame strategies.
doi:10.1016/j.ijid.2010.02.619
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Inﬂuenza vaccine: Immunization rates, knowledge, atti-
tudes and practice of health care workers in Iran in
2008/09
Z. Khazaeipour1,∗, N. ranjbar novin2, N. Hoseini 1
1 Health deputy of Tehran University of Medical Science,
Tehran, Iran, Islamic Republic of
2 Research Development Centerof Imam Khomeini Hospital
Complex, tehran, Iran, Islamic Republic of
Background: Inﬂuenza is an important cause of excessive
morbidity and mortality each winter. Its short incubation
period and efﬁcient transmission from person to per-
son makes inﬂuenza hazardous to the patients and staff
in healthcare facilities. The aims of this study were to
determine inﬂuenza vaccine coverage and evaluate the
knowledge, attitudes and practice about inﬂuenza and vac-
cine.
Methods: This study was a cross-sectional survey that was
performed between October 2008 and February 2009 in 139
health care workers (HCWs) of health deputy of Tehran Uni-
versity of medical science, Tehran, Iran. They received a
self-administered questionnaire and then the research assis-
tant waited to collect them.
Results: The response rate to the questionnaire
was 96.5%. The inﬂuenza vaccination coverage for the
2008—2009 seasons was 66.9% (range, 45% to 62%). Most
HCWs (80.6%) had received an inﬂuenza vaccination in the
past, and 65.4% intended to receive vaccination in the
future year. The main reason given for being immunized
was effectiveness of inﬂuenza vaccine (51.4%). The main
reason given for not being immunized was concerned about
sideeffects (23.1%). The knowledge score for the 35 items
ranged from 0 to 34 (mean 17.37). Mean knowledge scores
differed between courses. There was no signiﬁcant differ-
ence in mean knowledge scores between female and male
(P > 0.05) None of independent variables included age, sex,
marital status, having children aged)16 years and courses
were signiﬁcant predictors of taking inﬂuenza immuniza-
tion.
Conclusion: In our study, despite high coverage rate of
inﬂuenza vaccination in comparison with other studies, we
would expect higher rate because of free vaccine availabil-
l
ats e451
ty. The study results indicate that there is the need for
n-going education of Inﬂuenza disease, vaccine action and
enters for Disease Control and Prevention (CDC) recom-
endation among HCWs to increasing vaccination rates.
oi:10.1016/j.ijid.2010.02.620
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ariable serological response to PPV in HIV-positive
atients — A need to review pneumococcal boost-prime
trategies?
. Brown1,∗, C. Rock2, C. Ní Bhuachalla1, T. Coulter1, C.
owling1, C. Bergin1
St. James’s Hospital, Dublin, Ireland
Cork University Hospital, Dublin, Ireland
Background: International guidelines recommend 23-
olyvalent polysaccharide pneumococcal vaccination (PPV)
or HIV-positive patients with CD4 >200 cells/mm3. His-
orical data shows suboptimal response to vaccination in
IV-positive patients when measured by pneumococcal-
peciﬁc IgG and vaccine serotype-speciﬁc IgG2. There is
ittle data to support the efﬁcacy of vaccination in consis-
ently producing serological response, or assessing the role
f conjugate vaccine in adults.
Methods: In a cross-sectional study, 82 random sam-
les were taken from HIV-positive outpatients. The samples
ere assessed for pneumococcal IgG and IgG2. IgG2 lev-
ls >69g/L are considered good serological evidence of
esponse in the absence of baseline titres with which to com-
are post-vaccination response. Demographic, vaccination
nd laboratory data was recorded. Results were analysed
sing Fisher’s exact test and two-tailed p values with Graph-
ad InStat.
Results: Four patients were excluded with no prior his-
ory of pneumococcal vaccination, and two for incomplete
ata. The remaining 76 patients(M = 47, F = 29) were aged
etween 21 and 71 years (mean = 39.1yrs, SD 9.86) at the
ime of ﬁrst vaccination. Twenty-six patients (34%) received
ooster. Sixty-one patients (80%) were taking ART at the time
f sampling. Thirteen patients (17.1%) had vaccine serotype-
peciﬁc IgG2 titre ‘‘69g/L at the time of sampling.
chieving an IgG2 titre’’ 69g/L was not associated with
ny of the measured variables —– age < vs ‘‘35 yrs at vaccina-
ion(p = 0.54); male vs female sex(p = 0.54); CD4 count <200
s’’ 200 cells/mm3 at ﬁrst vaccination(p = 0.58); CD4 count
350 vs >350 cells/mm3 at ﬁrst vaccination(p = 1.00); CD4
ount <350 vs >350 cells/mm3 at time of sampling(p = 0.34);
RT at sampling time vs no ART(p = 1.00); single vs boosted
oses(p = 0.19); <234 weeks (4, years) since vaccination vs
‘234 weeks(p = 0.37).
Conclusion: In the HAART era only a minority of patients
how adequate levels of vaccine serotype-speciﬁc IgG2
egardless of time since vaccination or booster dosing.ogical response to PPV. Further studies are needed to
ssess the nature of response to PPV, alternative conju-
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and how the vaccine relates to sexual activity were the
most signiﬁcant predictors of vaccine uptake. Future public
health HPV vaccine campaigns must address these issues.
doi:10.1016/j.ijid.2010.02.623452 14
ate prime-boosting strategies, and the cost-effectiveness
f mass-vaccination programmes.
oi:10.1016/j.ijid.2010.02.621
3.019
he generation of immortalized human B-lymphocytes
ecreting neutralizing monoclonal antibodies against
engue virus
. Teoh
National University of Singapore, Singapore, Singapore
Background: Dengue is an important re-emerging disease
ffecting humans in more than 100 countries worldwide.
resently, over 2.5 billion people live in risk areas and 50
o 100 million people suffer from dengue fever (DF) each
ear. The World health Organization (WHO) estimates that
urrently 500,000 cases of Dengue Hemorrahagic Fever /
engue Shock Syndrome (DHF/DSS) and more than 20,000
eaths occur per year. At the moment, there are no
ffective vaccines or drugs available to prevent or treat
engue disease. Chimeric viruses, DNA, inactivated and sub-
nit recombinant vaccines are also of interest but they
re still in preclinical development. At present, vaccine
ay not be available for the next 3-5 years because the
omplex immune reactions that are involved in dengue
mmunopathogenesis needs further clariﬁcation. In this
tudy, we propose a novel method of immortalizing and
loning Dengue virus speciﬁc B lymphocytes from conva-
escent patients secreting neutralizing antibodies. Upon
hich, DNA from these B lymphocytes were extracted and
equenced. Sequential cloning method was employed to
lone in the variable light (VL) chain and variable heavy
VH) chain fragments into the IgG1 framework vector. This
ecombinant vector was transfected into suspension human
mbryonic kidney (HEK) 293 cells for transient expression
f the dengue-neutralizing antibodies belonging to the vari-
us IgG subclasses. The antibodies isolated will prove useful
ools for studying the immunology of Dengue virus infections
nd as possible future therapeutic reagents to prevent virus
issemination in infected individuals.
Methods: Ebv immortalization. ELISA. PRNT. Immunoﬂu-
rescent Microscopy. Molecular Cloning. Antibody puriﬁca-
ion.
Results: Antibody generated.
Conclusion: Human antibody responses are important
o resolve Dengue infections naturally and the best strat-
gy is to isolate and produce the anti-dengue antibodies
hat resolve infections in human patients. These thera-
eutic antibodies are have predictable pharmacokinetics
roperties and display low toxicological risk. A research col-
aboration involving the National University of Singapore
NUS), Novartis Institute of Tropical Diseases, Singapore
NITD) and Defence Science National Laboratories, Singa-
ore (DSO) aims to produce human monoclonal antibodies
mAb), that can efﬁciently neutralize the Dengue virus. Each
ntibody will be fully cloned and expressed recombinantly
s IgG class.
oi:10.1016/j.ijid.2010.02.622ternational Congress on Infectious Diseases (ICID) Abstracts
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actors Contributing to Uptake of the Publicly-funded HPV
accine in Toronto
. Meghani1,∗, V. Dubey2, O. Kadri 2, A. Mathur2, J.
ameron2, K. Beckermann2
University of Toronto, Toronto, ON, Canada
Toronto Public Health, Toronto, ON, Canada
Background: In August 2007 the Government of Ontario
nnounced that, for the ﬁrst time, it was offering the
uadravalent HPV vaccine to grade 8 females in all Toronto
chools beginning September 2007. Uptake of the vaccine in
he 2007/2008 province-wide program was much lower than
nticipated. The provincial HPV vaccination rate was 58%
or the ﬁrst dose, which was lower than other school-based
accination programs. For a vaccine with such far-reaching
mpact on a woman’s health, this is a disappointing and not
ell understood outcome. We assessed parental factors for
nd against the HPV vaccine.
Methods: A random sample of parents of grade 8 females
n Toronto who were eligible for the publicly-funded HPV
accine in the 2007-2008 academic session were asked to
espond to questions regarding the HPV vaccine program
n Toronto. We conducted telephone interviews and used
tandardized questionnaires to capture data. We conducted
ivariate statistics to compare the responses of parents who
llowed their daughters to be vaccinated against HPV with
hose of parents who did not. Multivariate logistic regression
tatistics was calculated with SPSS to identify the predictive
actors that were signiﬁcantly associated with HPV vaccine
ptake.
Results: Of the 138 respondents, 75.4% had vaccinated
heir daughters. Concern over safety of the vaccine (27.3%)
nd inadequate information (21.2%) were the most com-
only reported reasons given by parents to not allow their
aughters to be vaccinated. Religious afﬁliation was not
ssociated with a difference in parental decision to vacci-
ate. Parents whose daughters were vaccinated were more
ikely to agree with the importance of vaccination prior to
exual activity onset (OR=10.46, 95% CI: 1.72-63.59, p<0.05)
han parents whose daughters were not vaccinated. Par-
nts whose daughters were vaccinated were less likely to
gree that vaccination would encourage earlier sexual activ-
ty (OR=0.14, 95% CI: 0.02-0.91, p<0.05) than parents who
id not approve vaccination for their daughters.
Conclusion: Parents need more information about safety
nd efﬁcacy of the vaccine. Parental attitudes towards the
mportance of vaccinating before becoming sexually active
